These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1580 related articles for article (PubMed ID: 15117980)

  • 1. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
    Hanna N; Shepherd FA; Fossella FV; Pereira JR; De Marinis F; von Pawel J; Gatzemeier U; Tsao TC; Pless M; Muller T; Lim HL; Desch C; Szondy K; Gervais R; Shaharyar ; Manegold C; Paul S; Paoletti P; Einhorn L; Bunn PA
    J Clin Oncol; 2004 May; 22(9):1589-97. PubMed ID: 15117980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed versus docetaxel in second line non-small-cell lung cancer: results and subsets analyses of a multi-center, randomized, exploratory trial in Chinese patients.
    Li R; Sun L; Wang J; Qian J; Wang Z; Jiao X
    Pulm Pharmacol Ther; 2012 Oct; 25(5):364-70. PubMed ID: 22766314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival without common toxicity criteria grade 3/4 toxicity for pemetrexed compared with docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a risk-benefit analysis.
    Pujol JL; Paul S; Chouaki N; Peterson P; Moore P; Berry DA; Salzberg M
    J Thorac Oncol; 2007 May; 2(5):397-401. PubMed ID: 17473654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
    Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer.
    Kotsakis A; Agelaki S; Vardakis N; Stathopoulos G; Vamvakas L; Kalykaki A; Kentepozidis N; Kontopodis E; Sfakiotaki G; Mavroudis D; Georgoulias V
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):415-22. PubMed ID: 21069335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer.
    Weiss GJ; Langer C; Rosell R; Hanna N; Shepherd F; Einhorn LH; Nguyen B; Paul S; McAndrews P; Bunn PA; Kelly K
    J Clin Oncol; 2006 Sep; 24(27):4405-11. PubMed ID: 16983108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study.
    Sun Y; Wu YL; Zhou CC; Zhang L; Zhang L; Liu XY; Yu SY; Jiang GL; Li K; Qin SK; Ma SL; Han L; Quinlivan M; Orlando M; Zhang XQ
    Lung Cancer; 2013 Feb; 79(2):143-50. PubMed ID: 23182660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.
    Hanna N; Shepherd FA; Fossella FV; Pereira JR; De Marinis F; von Pawel J; Gatzemeier U; Tsao TCY; Pless M; Muller T; Lim HL; Desch C; Szondy K; Gervais R; Shaharyar ; Manegold C; Paul S; Paoletti P; Einhorn L; Bunn PA
    J Clin Oncol; 2023 May; 41(15):2682-2690. PubMed ID: 37196429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer.
    Cohen MH; Johnson JR; Wang YC; Sridhara R; Pazdur R
    Oncologist; 2005; 10(6):363-8. PubMed ID: 15967829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).
    Ardizzoni A; Tiseo M
    J Chemother; 2004 Nov; 16 Suppl 4():104-7. PubMed ID: 15688623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pemetrexed: new drug. Pleural mesothelioma: a first encouraging trial.
    Prescrire Int; 2005 Dec; 14(80):212-4. PubMed ID: 16400741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Di BS; Wei KP; Tian JH; Xiao XJ; Li Y; Zhang XH; Yu Q; Yang KH; Ge L; Huang WH; Zhang FW
    Asian Pac J Cancer Prev; 2014; 15(8):3419-24. PubMed ID: 24870732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line chemotherapy for non-small-cell lung cancer: recent data with pemetrexed.
    Hanna NH
    Clin Lung Cancer; 2004 Apr; 5 Suppl 2():S75-9. PubMed ID: 15117429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
    Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
    Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status.
    Chen YM; Shih JF; Fan WC; Wu CH; Chou KT; Tsai CM; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2011 May; 74(5):209-14. PubMed ID: 21550007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
    Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
    J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.
    Kim YH; Hirabayashi M; Kosaka S; Nikaidoh J; Yamamoto Y; Shimada M; Toyazaki T; Nagai H; Sakamori Y; Mishima M
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1445-51. PubMed ID: 23532206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.
    Chung FT; Lee KY; Fang YF; Shieh MH; Lin SM; Yu CT; Lo YL; Lin TY; Kuo CH; Feng PH; Ni YL; Kuo HP
    Chemotherapy; 2011; 57(2):147-55. PubMed ID: 21454972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed: a multitargeted antifolate.
    Rollins KD; Lindley C
    Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.
    Weiss GJ; Rosell R; Fossella F; Perry M; Stahel R; Barata F; Nguyen B; Paul S; McAndrews P; Hanna N; Kelly K; Bunn PA
    Ann Oncol; 2007 Mar; 18(3):453-60. PubMed ID: 17322539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 79.